What is an FDA Form 483?

1What a Form 483 is.

FDA Form 483, Inspectional Observations, is issued to a company’s management at the end of an inspection “when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts”. Observations are made when the investigator judges that a food, drug, device or cosmetic has been adulterated, or is being prepared, packed or held under conditions in which it may become adulterated or injurious to health.¹

The form rests on the Act itself. Section 704(b) requires the inspector, on completing an inspection and before leaving the premises, to give the owner, operator or agent in charge “a report in writing setting forth any conditions or practices observed” that in their judgement indicate a product consists of any filthy, putrid or decomposed substance, or was prepared, packed or held under insanitary conditions.² FDA’s Investigations Operations Manual, as FDA quotes it, says the issuance of written inspectional observations “is mandated by law and ORA policy”.³

483s are issued across FDA’s programmes. FDA’s published 483 data covers biologics, drugs, devices, human tissue, foods, veterinary medicine and bioresearch monitoring, among others.⁴

2What goes on it, and what doesn’t.

FDA investigators are trained to make each observation “clear, specific and significant”.¹ An FDA presentation on drug inspections adds that a 483 holds only factual observations from the current inspection, with no opinions or assumptions, listed in order of significance. For drug manufacturers the principal regulation cited is 21 CFR Part 211, for example 211.22(a) for the lack of a quality control unit. Investigators note only what they saw during the inspection.³¹

A 483 is not a complete list of problems. It “does not include observations of questionable or unknown significance at the time of the inspection”, and other objectionable conditions may exist that were not cited. FDA says companies are responsible for correcting both the cited conditions and any related ones that were not cited.¹ Observations an investigator raises only in discussion can be addressed in the company’s response too.⁵

The form says so itself. Its preprinted instruction states that the observations “do not represent a final agency determination regarding your compliance”, and that a company may discuss an objection or a corrective action with the FDA representatives during the inspection or send it to FDA afterwards.⁶

3What happens at the close of the inspection.

The 483 is presented and discussed with senior management, and each observation is read so that both sides understand what it means.¹ A manufacturer of finished pharmaceuticals must have procedures to notify its responsible officials in writing of “reports of inspectional observations issued by the Food and Drug Administration” if they were not involved.⁷

FDA’s draft guidance of March 2026 recommends engaging with the FDA representatives during the inspection and at the closing meeting to clarify findings, and having management assess the related risks to product quality and patient safety straight away.⁵

4What happens after a 483.

FDA does not treat the 483 as its conclusion. It considers the 483 together with the Establishment Inspection Report, the evidence collected on site and any response from the company, then decides what further action, if any, is needed.¹

A response is not required, but FDA encourages one, in writing, with a corrective action plan.¹⁵ Since a programme it began in 2009, FDA has generally allowed 15 business days: a response received within that time gets a detailed review before FDA decides whether to issue a warning letter, and FDA will not ordinarily delay a warning letter to review a later one.⁶ The March 2026 draft guidance, which is not yet final, keeps that timeframe and sets out what a drug manufacturer’s response should contain.⁵ The page on responding to a Form 483 covers the response itself.

For drug CGMP inspections, FDA has told each site its classification within 90 days of the end of the inspection since 1 October 2018, as part of its generic drug user fee commitments.³

For significant violations, FDA’s principal tool is the warning letter, and an inspection is classified OAI whenever one is issued.⁸ The page on the difference between a 483 and a warning letter sets the two side by side.

5Where 483s are published.

Redacted drug CGMP 483s are generally posted only after three or more Freedom of Information Act requests, or proactively by FDA under specific conditions, with trade secret and confidential commercial information removed.³ FDA also publishes spreadsheets, by fiscal year from 2006 to 2025, that count how often each area of regulation was cited on 483s generated by its electronic inspection tools. They are not a complete list, because some 483s are prepared by hand.⁴ The page on looking up 483s and warning letters explains where to search.

6How it runs in Seal.

The inspection readiness blueprint logs observations, such as Form 483 items or audit findings, with the cited requirement and your response commitments. Follow-up actions link to CAPA, and verification evidence links back to the original observation, so an action is not treated as closed because a response letter was sent. During the inspection, each request keeps its wording, owner, evidence and delivery, and a delivered package keeps the source versions that were shown.

Neil can assemble the evidence behind a specific question and make missing evidence explicit; your audit owner checks scope and completeness before anything is shared, and Neil does not send records to the auditor. For the corrective actions themselves, the CAPA blueprint can require an approved effectiveness review before closure.